drugset / Trial / NCT02481518

Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity

NCT02481518

Phase 4 Completed 30 enrolled Mahidol University
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine whether magnesium preloading reduce incident of cisplatin induced acute kidney injury in head and neck cancer who receiving low dose cisplatin (40 mg/m2 weekly for 7 weeks).

Timeline

Start
2015-03
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified 16 meq Intravenous
Background Potassium Chloride Small molecule 20 meq Intravenous

Indications